Company Filing History:
Years Active: 2016-2019
Title: Innovations by Zachary Kaur in Insulin Analog Development
Introduction
Zachary Kaur is an accomplished inventor based in Bloomington, IN (US). He has made significant contributions to the field of biochemistry, particularly in the development of insulin analogs. With a total of 2 patents, his work focuses on enhancing the efficacy of insulin treatments.
Latest Patents
Kaur's latest patents include innovative single-chain insulin agonists that exhibit high activity at the insulin receptor. These single-chain insulin analogs are designed to have high potency and specificity for the insulin receptor. The patents disclose the use of optimally sized linking moieties to connect human insulin A and B chains, or their analogs and derivatives. Specifically, the carboxy terminus of the B25 amino acid of the B chain is linked to the amino terminus of the A1 amino acid of the A chain via the intervening linking moiety. One embodiment of the linking moiety comprises a polyethylene glycol of 6-16 monomer units, while an alternative embodiment includes a non-native amino acid sequence derived from the IGF-1 C-peptide, consisting of at least 8 and no more than 12 amino acids in length. Additionally, the patents disclose prodrug and conjugate derivatives of these single-chain insulin analogs.
Career Highlights
Zachary Kaur is affiliated with Indiana University, where he continues to advance research in insulin analogs. His work has the potential to significantly impact diabetes treatment and management.
Collaborations
Kaur collaborates with notable colleagues such as Richard Dennis DiMarchi and Yulia Azriel, contributing to a dynamic research environment focused on innovative solutions in biochemistry.
Conclusion
Zachary Kaur's contributions to the field of insulin analog development highlight his role as a leading inventor in biochemistry. His innovative patents and collaborations pave the way for advancements in diabetes treatment.